# Early Aortic Valve Lipoprotein(a) Lowering Trial

> **NCT02109614** · EARLY_PHASE1 · WITHDRAWN · sponsor: **George Thanassoulis**

## Conditions studied

- Aortic Stenosis and Lipoprotein(a) Levels

## Interventions

- **DRUG:** Extended release Niacin
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT02109614
- **Lead sponsor:** George Thanassoulis
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-05
- **Primary completion:** 2017-01
- **Final completion:** 2017-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2023-10-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109614, "Early Aortic Valve Lipoprotein(a) Lowering Trial". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02109614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*